Le Lézard
Classified in: Health
Subject: RCL

Sleep Dallas Launches Initiative to Help Patients Impacted by the Philips CPAP Recall


IRVING, Texas, Sept. 10, 2021 /PRNewswire/ -- More than 60 days have passed since the recall of 4 million ventilation and sleep apnea devices by Royal Philips NV. Since then, an estimated 38,000 people suffering from sleep apnea across North Texas have been left to find answers ? largely on their own. They have been faced with the life-altering decision of stopping use altogether or continuing to use a machine that could be releasing potentially cancer-causing gases and particles into their bodies.

Philips estimates it will take up to a year to fully correct the defect in all devices. At the same time, alternate CPAP's have scarce availability due to shortages of key components.

"Over the last 25 years, we have helped thousands of patients treat the debilitating effects of sleep apnea. Now, they need us more than ever," commented Dr. Kent Smith, Chief Medical Officer of Sleep Dallas. He continued, "We are proud to offer our expertise ? at no out-of-pocket cost or obligation ? to these patients. They deserve answers and solutions."

Sleep Dallas is launching this initiative on Monday, September 13, 2021. The goal is to provide patients with "no cost" consultations and personalized solutions on how best to handle the impact of the Philips recall. Patients will be able to register for an appointment via the Sleep Dallas website at https://www.sleepdallas.com/?utm_source=pr or by calling (469) 405-1460.

Where:           290 E John Carpenter Freeway, #2700
                        Irving, TX   75062

                        7589 Preston Road, Suite 400
                        Frisco, TX   75034

When:             Starting Monday, September 13, 2021

Who:               Dr. Kent Smith and Dr. Maria Dibra

Reference Information:

More about Sleep Dallas:
As the only practice in North Texas to combine the expertise of a sleep physician and a sleep dentist, Sleep Dallas provides a much more comprehensive array of treatment options. Founded in 1997 by Dr. Kent Smith, Sleep Dallas has helped more than 20,000 patients successfully treat their sleep apnea. Sleep Dallas is unique in that it: offers multiple treatment options to patients; is in-network with nearly all major insurance providers; provides a whole-health approach to quality sleep; and delivers continued care after initial treatment.

Their "no cost" consultation is a commitment that no patient will incur an out-of-pocket cost for the initial meeting and recommendations. If the patient has insurance, it will be utilized. If not, Sleep Dallas will be responsible for the related expenses.

More About the Philips Respironics Recall:
The United States Food and Drug Administration (FDA) has given this recall its most serious classification indicating the situation could lead to serious health issues. There are numerous sources of information regarding the recall, including two articles written by Denise Roland in the Wall Street Journal

Additional information about the recall can be found at:

Contact Information:

Website: https://www.sleepdallas.com/?utm_source=pr 

Dr. Kent Smith, Clinical Director
Sleep Dallas
7589 Preston Road, Suite 400
Frisco, TX   75034
(972) 365 ? 5141 (cell)

Candy Chaney, Client Relations
TNT Dental
2100 North Collins Boulevard
Richardson, TX   75080
(318) 469 ? 9363 (cell)

SOURCE Sleep Dallas


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: